Relay Therapeutics Company Insiders

Relay Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.2537) % which means that it has lost $0.2537 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4115) %, meaning that it created substantial loss on money invested by shareholders. Relay Therapeutics' management efficiency ratios could be used to measure how well Relay Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Relay Therapeutics owns a total of 173.32 Million outstanding shares. The majority of Relay Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Relay Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Relay Therapeutics. Please pay attention to any change in the institutional holdings of Relay Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Relay Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Relay Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Relay Therapeutics Workforce Comparison

Relay Therapeutics Insider Trading

Relay Therapeutics Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Relay Therapeutics often depends on how effective the management is. Relay Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Relay management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Relay management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Relay Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Relay Therapeutics. Check Relay Therapeutics' Beneish M Score to see the likelihood of Relay Therapeutics' management manipulating its earnings.

When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.